Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer

PDAC - Pancreatic Ductal Adenocarcinoma Clinical Trial

— PanC-YOUNG  

Official title:

Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05845801
• Other study ID #: 3968
• Status: Recruiting
• Start date: December 7, 2022
• Est. completion date: September 30, 2052

Study information

• Verified date: May 2023
• Source: Azienda Ospedaliera Universitaria Integrata Verona
• Contact: Fabio Casciani
• Phone: 0458124671
• Email: fabio.casciani[@]univr.it
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The objective of the present registry is the creation of a prospective registry collecting clinico-pathological and genomic data, along with survival outcomes, of individuals diagnosed with PDAC at or before the age of 55 years old. This registry is intended with the aim of using collected data for future clinical trials, both prospective and retrospective.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: September 30, 2052
• Est. primary completion date: September 30, 2052
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Age =55 years old at the time of diagnosis of pancreatic cancer
• Age = 18 years
• Written informed consent obtained.

Exclusion Criteria:

• Any pancreatic neoplasm other than pancreatic cancer (e.g. cholangiocarcinoma, ampullary cancer,duodenal cancer, non-invasive mucinous cystic neoplasm, pancreatic intra-epithelial neoplasia 1 and 2, non-invasive intraductal papillary mucinous neoplasm, serous cystic neoplasm, pseudo papillary solid tumor, neuroendocrine tumor)
• Absence of informed consent.
• Age < 18 years or > 55 years old at the time of diagnosis of pancreatic cancer

Related Conditions & MeSH terms

• PDAC - Pancreatic Ductal Adenocarcinoma

Intervention

Other:
• Register
Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old.

Locations

Country	Name	City	State
Italy	AOUI Verona	Verona

Sponsors (1)

Lead Sponsor	Collaborator
Azienda Ospedaliera Universitaria Integrata Verona

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Register of young PDAC patients	Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old.	30 years